Shoreline Biome to present strain-level rRNA amplicon research at AGBT 2020

Poster to feature differential microbiome response to sepsis detected using strain-level rRNA amplicon

FARMINGTON, Conn.— Shoreline Biome, a microbiome research company that develops tools for characterizing microbiome populations down to the strain level, will present a poster at the 2020 Advances in Genome Biology and Technology (AGBT) General Meeting.

The poster, titled “Differential Microbiome Response to Sepsis Detected Using Strain Level rRNA Amplicon,” will be presented by Mark Driscoll, Ph.D., Shoreline Biome’s co-founder and CSO. It is based on research by Driscoll and Dawn Gratalo of Shoreline Biome and Allison L. Brichacek and Candice M. Brown, Ph.D. of West Virginia University School of Medicine’s Department of Neuroscience.

Scientists do not yet fully understand the relationship between sepsis and dementia, but sepsis can change the gut microbiome in ways that affect health and behavior. Dr. Brown and her team conducted strain-level

microbial profiling using Shoreline Biome’s StrainID kit and revealed that microbial communities change in response to sepsis.

Microbiome profiling of rRNA gene amplicons is a well-understood method that is rapid and inexpensive, but standard short-read 16S rRNA gene methods generally cannot differentiate between closely related strains—important for understanding the relationship between the gut microbiome and human health. When Shoreline Complete StrainID amplicons are run on the PacBio Sequel, the combination of non-bead-beating lysis, comprehensive PCR primer pools, a 16S-ITS-23S amplicon product, and Shoreline Biome’s long-read Athena database enable differentiation of closely related strains within and across samples using a simple, rapid, and cost-effective approach.

The Advances in Genome Biology and Technology General Meeting is considered the preeminent genome science and technology conference at which top global researchers, leaders, and innovators meet to announce new discoveries, cutting edge breakthroughs and to collaborate. It will be held February 23–26, 2020, at Marco Island, Florida. For more information about the conference, visit agbt.org.

Characterizing the human microbiome, and analyzing its role in human health and disease, are priority goals for researchers around the world. Shoreline Biome accelerates breakthroughs in microbiome research by developing transformative discovery tools that characterize microbiome populations down to the strain level. With Shoreline Biome products, all it takes is three easy steps: lyse, purify, and amplify. Shoreline Biome’s easy-to-use companion analysis software and comprehensive reference database enables straightforward strain-level identification and quantitation of all bacteria in the sample. To learn more, visit shorelinebiome.com.

For more information contact:

Bill McKenzie, CEO
617-817-0929
Bill.McKenzie@ShorelineBiome.com